UBS AM
BHVN

UBS AM’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

UBS AM’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-63,992
Closed -$9.67M – 2824
2022
Q3 		$9.67M Sell
63,992
-274,722
-81% -$40.7M 0.01% 971
2022
Q2 		$49.4M Buy
338,714
+278,098
+459% +$35.5M 0.03% 553
2022
Q1 		$7.19M Buy
60,616
+4,239
+8% +$529K ﹤0.01% 1197
2021
Q4 		$7.77M Buy
56,377
+1,460
+3% +$186K ﹤0.01% 1221
2021
Q3 		$7.63M Buy
54,917
+563
+1% +$70.3K ﹤0.01% 1194
2021
Q2 		$5.28M Buy
54,354
+2,251
+4% +$183K ﹤0.01% 1345
2021
Q1 		$3.56M Buy
52,103
+2,518
+5% +$204K ﹤0.01% 1500
2020
Q4 		$4.25M Buy
49,585
+4,627
+10% +$392K ﹤0.01% 1367
2020
Q3 		$2.92M Buy
44,958
+283
+0.6% +$18.5K ﹤0.01% 1381
2020
Q2 		$3.27M Sell
44,675
-6,445
-13% -$343K ﹤0.01% 1315
2020
Q1 		$1.74M Sell
51,120
-2,285
-4% -$104K ﹤0.01% 1470
2019
Q4 		$2.91M Sell
53,405
-140,353
-72% -$6.95M ﹤0.01% 1441
2019
Q3 		$8.08M Buy
193,758
+14,942
+8% +$631K 0.01% 1033
2019
Q2 		$7.83M Buy
178,816
+171,904
+2,487% +$9.69M 0.01% 1037
2019
Q1 		$356K Hold
6,912
– – ﹤0.01% 2243
2018
Q4 		$256K Buy
6,912
+312
+5% +$11.2K ﹤0.01% 2277
2018
Q3 		$248K Buy
+6,600
New +$243K ﹤0.01% 2349

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

UBS AM's BHVN Position: Q4 2022 in Review

UBS AM sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 63,992 shares — an estimated $9.67M sold.

UBS AM first reported a position in BHVN in Q3 2018 and held it in 17 quarters. The position peaked at $49.4M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • UBS AM reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • UBS AM sold 63,992 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $9.67M.
  • UBS AM first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 17 quarters.
  • UBS AM's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $49.4M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.